The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
source sync and i think that's dynamic and that's something that we've been talking about recently source habitat sink habitats the idea that you've got habitats that are uh have have very good blood supply that they produce a lot of cells but they and then now they're producing too many cells for the spatial environment and those cells have to go out
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
but you mentioned actually something that's that's I think important in Source sync and I think that's a dynamic and that's something that we've been talking about recently Source habitats sink habitats the idea that you've got habitats that are uh have have very good blood supply that they produce a lot of cells but they and then now they're producing too many cells for the spatial environment and those cells have to go out and um one can think of those within the cells so that you've got areas with poor blood flow and uh areas of good blood flow next to one another and you can imagine cells migrating between
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.